Dexcom Inc (NASDAQ: DXCM) is a medical device company that designs, develops, and manufactures continuous glucose monitoring (CGM) systems. Revenue is generated through the sale of CGM hardware sensors and transmitters, with sensors consumed on a recurring basis by patients, creating a high-frequency consumable revenue stream. Dexcom is listed on the Nasdaq Global Select Market. The filing confirms the company is a well-known seasoned issuer as of its 10-K filed February 12, 2026, covering fiscal year ended in 2025. The aggregate market value of common stock held by non-affiliates was approximately $87.29 per share as of June 30, 2025, the last business day of the second fiscal quarter.

Revenue model

Transactional and consumable-driven. Dexcom sells CGM sensors, transmitters, and receivers directly and through distribution channels. Sensors are worn-and-replaced devices, generating repeat purchases from existing patients.

Products and services

Continuous glucose monitoring (CGM) systems, including wearable sensors, transmitters, and receivers, sold under the Dexcom brand.

Customers and end markets

Diabetes patients (type 1 and type 2) and healthcare providers. Products are distributed through pharmacy, durable medical equipment, and direct channels.

Value-chain role

Medical device manufacturer and direct-to-patient and channel distributor of CGM systems.

Geographic exposure

Filing does not provide a geographic revenue breakdown in the excerpts provided.

Source: SEC 10-K, filed 2026-02-12

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Baxter International Inc Becton Dickinson and Co Boston Scientific Corp Edwards Lifesciences Corp IDEXX Laboratories Inc Intuitive Surgical Inc Resmed Inc Stryker Corp Zimmer Biomet Holdings, Inc